Immunogenicity and safety of hepatitis B vaccine (Shanvac-B) using a novel pre-filled single use injection device uniject in Indian subjects

Indian Journal of Medical Sciences

Volumn 58, Issue 11, 2004, Pages 471-477

  Joshi, N ^a,b   Kumar, A ^a,b   Raghu, M B ^c   Bhave, S ^d   Arulprakash, R ^e   Bhusari, P ^e   Rao, Raman ^d,e  

^a NIZAM'S INSTITUTE OF MEDICAL SCIENCES   (India)

^b SRI RAMACHANDRA UNIVERSITY   (India)

^c KEM HOSPITAL   (India)

^d Clinical Research Division   (India)

^e Shantha Biotechnics Ltd   (India)

Author keywords

Hepatitis B vaccine; Pre filled device; Uniject

Indexed keywords

RECOMBINANT HEPATITIS B VACCINE; HEPATITIS B VACCINE;

ADULT; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; CRYING; DIZZINESS; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; EDEMA; FEMALE; FEVER; HEADACHE; HEPATITIS B; HUMAN; IMMUNITY; IMMUNOGENICITY; INJECTION PAIN; INJECTION SITE REACTION; IRRITABILITY; JET INJECTION; MALAISE; MALE; NEWBORN; PRURITUS; SKIN MANIFESTATION; TREATMENT OUTCOME; VACCINATION; VOMITING; ADOLESCENT; COHORT ANALYSIS; COMPARATIVE STUDY; DISEASE TRANSMISSION; DRUG PACKAGING; EQUIPMENT; IMMUNIZATION; IMMUNOLOGY; INDIA; INSTRUMENTATION; METHODOLOGY; MIDDLE AGED; SENSITIVITY AND SPECIFICITY; SUBCUTANEOUS DRUG ADMINISTRATION;

ADOLESCENT; ADULT; COHORT STUDIES; DISEASE TRANSMISSION, HORIZONTAL; DRUG PACKAGING; EQUIPMENT SAFETY; FEMALE; HEPATITIS B; HEPATITIS B VACCINES; HUMANS; IMMUNIZATION SCHEDULE; INDIA; INFANT, NEWBORN; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; SENSITIVITY AND SPECIFICITY; VACCINATION;

EID: 11444259213     PISSN: 00195359     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Prevention of hepatitis B in India. An overview. World Health Organization; 2002.
2. th Ed. Park's Textbook of Preventive and Social medicine. India: Banarsidas Bhanotl 2002;159-67.
3. Indian Association for Study of the Liver (INASL). Hepatitis B in India: Therapeutic options and prevention strategies - Consensus statements. Ind J Gastroenterol 2000;19:54-74.
4. Hilleman MR, McAleer WJ, Buynak EB, McLean AA. The preparation and safety of hepatitis B vaccine. J Infect 1983;7:3-8.
5. McAleer WJ, Buynak EB, Maigetter RZ, Wampler DE, Miller WJ, Hilleman MR. Human hepatitis B vaccine from recombinant yeast. Nature 1984;307:178-80.
6. Harford N, Cabezon T, Colau B, Delisse AM, Rutgers T, De Wilde M. Construction and characterization of a Saccharomyces cerevisiae strain (RIT4376) expressing hepatitis B surface antigen. Postgrad Med J 1987;63:65-70.
7. Abraham P, Mistry FP, Bapat MR, Sharma G, Reddy GR, Prasad KS, et al. Evaluation of a new recombinant DNA hepatitis B vaccine (Shanvac-B). Vaccine 1999;17:1125-9.
8. Samuels ME, Koop CE, Hartsock PI. Single-use syringes. N Engl J Med 1991;324:996-7.
9. Report of 1993 Technet Conference. Geneva, World Health Organization, (unpublished document WHO/EPI/LHIS/93.1; available upon request from Expanded Programme on Immunization, World Health Organization, 1211 Geneva 27, Switzerland; 1993.
10. Sutanto A, Suarnawa IM, Nelson CM, Stewart T, Soewarso TI Home delivery of heat-stable vaccines in Indonesia: Outreach immunization with a prefilled, single-use injection device. Bull WHO 1999;77:119-26.
11. Kumar TS, Abraham P, Raghuraman S, Cherian T. Immunogenicity of indigenous recombinant hepatitis B vaccine in infants following a 0, 1, 2-month vaccination schedule. Indian Pediatr 2000;37:75-80.
12. Joshi N, Kumar A, Sreenivas DV, Palan S, Nagarjuna Kumar YR. Safety and immunogenicity of indigenous recombinant hepatitis B vaccine (Shanvac-B) in comparison with commercially available vaccine. Indian J Gastroenterol 2000;19:71-3.
13. Otto BF, Suarnawa IM, Stewart T, Nelson C, Ruff TA, Widjaya A, Maynard JE. At-birth immunisation against hepatitis B using a novel pre-filled immunisation device stored outside the cold chain. Vaccine 1999;18:498-502.
14. World Bank. World Development Report 1993. Investing in Health. Oxford: Oxford University Press; 1993. p. 27.
15. Hepatitis B immunization. Introducing hepatitis B into national immunization services. (Fact sheet.) Geneva, (unpublished document WHO/V&B/01.28; available from Vaccines and Biologicals, World Health Organization, 1211 Geneva 27, Switzerland, 2001 and on the Internet at www.who.int/vaccines-documents/DocsPDF01/www598.pdf).
16. Kumar ST, Abraham P, Raghuraman S, Cherian T. Immunogenicity of indigenous recombinant Hepatitis B vaccine in infants following a 0, 1, 2 - month vaccination schedule. Indian Pediatr 2000:37;75-80.
17. Joshi N, Kumar A, Sreenivas DV, Palan S, Kumar YR. Safety and Immunogenicity of indigenous recombinant hepatitis B vaccine (Shanvac-B) in comparison with commercially available vaccine. Indian J Gastroentrol 2000:19;71-3.
18. Goldfarb J, Baley J, Medendorp SV, Seto D, Garcia H, Toy P, et al. Comparative study of the immunogenicity and safety of two dosing schedules of Engerix-B hepatitis B vaccine in neonates. Pediatr Infect Dis J 1994;13:18-22.